Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

NVO TEVA AGN FRX Realty Toys Emerging Markets 
Benchmark  United States  NYSE  10,402   42.535 Index Moved Up 0.41%  

Processing. Please wait...

Sucampo insider: Ryuji Ueno


Ryuji Ueno - Sucampo Insider Profile

Chairman of the Board, CEO, Chief Scientific Officer

Dr. Ryuji Ueno M.D. Ph.D. is no longer Chairman of the Board Chief Executive Officer of Sucampo Pharmaceuticals Inc. effective March 3 2014 and Chief Scientific Officer effective March 31 2014. Dr. Ueno became a director in 1996 is a cofounder of company and was Company chief executive officer since September 2006 and Company chief scientific officer since August 2004. Dr. Ueno also became the chairman of Company board of directors effective June 1 2007. Dr. Ueno served as chairman of Company board of directors from December 2000 to September 2006. He also served as chief operating officer from December 1996 to November 2000 and again from March 2006 to September 2006 and as chief executive officer from December 2000 to September 2003. Dr. Ueno cofounded RTech a related pharmaceutical research development and manufacturing company in Japan in September 1989 and served as its President from 1989 to March 2003. In 2010 Dr. Ueno became President of Omotesenke Domonkai Tobushibu a cultural and educational organization for the Eastern United States
Age: 58  Chairman Since 2014  Ph.D    

Other Appointments

Ryuji Ueno EducationUeno earned his M.D. and a Ph.D. in medicinal chemistry from Keio University in Japan, and earned a Ph.D. in Pharmacology from Osaka University . He conducted postgraduate research at Cold Spring Harbor Lab and Kyoto University Department of Medicinal Chemistry.

Management Efficency

The company has return on total asset (ROA) of 6.47 % which means that it generated profit of $6.47 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 12.69 % meaning that it created $12.69 on every $100 dollars invested by stockholders.
The company currently holds 52.72 M in liabilities with Debt to Equity (D/E) ratio of 0.91 which is about average as compared to similar companies. Sucampo Pharmaceuticals Inc has Current Ratio of 2.61 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Sucampo price boundaries

March 28 2014
Lowest period price (30 days)
March 17 2014
Highest period price (30 days)

Entity Summary

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. Sucampo Pharmaceuticals Inc [SCMP] is traded on NASDAQ General Markets in USA. It is located in Sucampo Pharmaceuticals, Inc.Bethesda, MD and employs 128 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
Showing first 30 of many records found


Jesper MScNovo Nordisk AS
David PyottAllergan Inc
MS Eng)Dr Reddys Laboratories Ltd
Martine RothblattUnited Therapeutics Corporation
Robert DugganPharmacyclics Inc
Goran AndoNovo Nordisk AS
Pr KrinskyTeva Pharmaceutical Industries
Christopher PatuskyUnited Therapeutics Corporation
Sten ScheibyeNovo Nordisk AS
William FarberLannett Company Inc
MS BTechDr Reddys Laboratories Ltd
Brenton JDForest Laboratories Inc
Roger KimmelEndo International plc
Ronald WestLannett Company Inc
Stanley CrookeIsis Pharmaceuticals Inc
Dr MDIsis Pharmaceuticals Inc
Arthur JDLannett Company Inc
Peter StapleDepoMed Inc
Howard SolomonForest Laboratories Inc
Jeffrey FarberLannett Company Inc
K ReddyDr Reddys Laboratories Ltd
Sucampo Pharmaceuticals Inc
USA Stock
Currency: USD - US Dollar
Traded on NASDAQ General Markets

Fix Your Portfolios with Sucampo

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Sucampo Pharmaceuticals Inc to your portfolio

Promote Sucampo and Ryuji Ueno

Follow Sucampo with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker

Sucampo Pharmaceuticals Leadership

James Egan, COO
Barbara Munder, Director, MBA
James JD, COO
Peter Lichtlen, President, Ph.D
Thomas JD, EVP
Anthony Celeste, Director
Gayle Dolecek, Director
Kei Tolliver, Director
Stanley Miele, President
Daniel Getman, Director, Ph.D
, MD, Chairman
Ryuji Ueno, Chairman, Ph.D
Silvia Taylor, President, MBA
Peter MD, VP
Thomas Knapp, President
Sachiko Kuno, Director, Ph.D
William Ashton, Director
Cary Claiborne, CFO, MBA
Andrew Smith, Executive
MPH PD, Director
Maureen OConnell, Director
Timothy Maudlin, Director
Peter Greenleaf, CEO, MBA
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Find Alpha
Equity Screener
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and families
Research Equities
Insiders Screener
Find insiders across different sectors to evaluate their impact on performance and growth of their entities
Research Insiders

Stock Performance

Shares Outstanding42.79 M
Number of Shares Shorted1.78 M